NCT04873050 - Treatment to Regress to Normoglycemia in Women with a Recent History of GDM | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

January 13, 2022

Primary Completion Date

January 1, 2026

Study Completion Date

March 1, 2026

Conditions

Pre DiabetesPostpartum Disorder

Interventions

DRUG

Semaglutide Pen Injector [Ozempic]

Start injection of semaglutide 0.25mg subcutaneously (SC) once a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses

DRUG

Placebo semaglutide pen injector

Start injection of placebo semaglutide 0.25mg subcutaneously (SC) one a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses

Trial Locations (1)

70817

RECRUITING

Woman's Hospital, Baton Rouge